We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
(+3%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-8.52%
Top 10 Holdings %
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22
Avg Time Held Equity + Options
7.7
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
7.5
quarters
Avg Time Held Equity only
8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
7.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.42% |
| 2 | Miscellaneous | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
PTC Therapeutics
PTCT
$5.03B
| $3.35M | 0.07% |
49,100
+25,900
| +112% | +$1.83M |
2025 Q4
1 quarter
|
|
102
Lifestance Health
LFST
$4.69B
| $3.19M | 0.06% |
+500,000
| New | +$3.48M |
2026 Q1
0 quarters
|
|
103
Bright Minds Biosciences
DRUG
$518M
| $2.92M | 0.06% |
+40,000
| New | +$3.22M |
2026 Q1
0 quarters
|
|
104
Jade Biosciences
JBIO
$865M
| $2.6M | 0.05% |
185,011
-346,152
| -65% | -$5.01M |
2025 Q2
3 quarters
|
|
105
C4 Therapeutics
CCCC
$346M
| $2.25M | 0.04% |
856,353
-548,549
| -39% | -$1.29M |
2024 Q2
7 quarters
|
|
106
DELISTED
KalVista Pharmaceuticals
KALV
| $1.9M | 0.04% |
94,400
-288,000
| -75% | -$4.64M |
2025 Q4
1 quarter
|
|
107
ImageneBio Inc
IMA
$47M
| $1.89M | 0.04% |
378,556
| – | – |
2021 Q1
20 quarters
|
|
108
VistaGen Therapeutics
VTGN
$9.55M
| $1.75M | 0.03% |
3,060,000
| – | – |
2025 Q3
2 quarters
|
|
109
DELISTED
AtaiBeckley Inc
ATAI
| $1.23M | 0.02% |
+347,000
| New | +$1.31M |
2026 Q1
0 quarters
|
|
110
Traws Pharma
TRAW
$6.38M
| $1.11M | 0.02% |
605,531
| – | – |
2024 Q2
7 quarters
|
|
|
111
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-2,429,868
| Closed | -$61M | – |
|
112
Bruker
BRKR
$8.54B
| – | – |
-555,789
| Closed | -$26.2M | – |
|
113
Celcuity
CELC
$3.1B
| – | – |
-85,664
| Closed | -$8.54M | – |
|
|
114
Cigna
CI
$74.7B
| – | – |
-205,000
| Closed | -$56.4M | – |
|
115
CytomX Therapeutics
CTMX
$519M
| – | – |
-3,525,650
| Closed | -$15M | – |
|
116
CALL
Edwards Lifesciences
EW
$49.4B
| – | – |
-150,000
| Closed | -$12.8M | – |
|
117
DELISTED
Exact Sciences
EXAS
| – | – |
-351,716
| Closed | -$35.7M | – |
|
118
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-729,900
| Closed | -$10.4M | – |
|
119
Insmed
INSM
$21.2B
| – | – |
-25,400
| Closed | -$4.42M | – |
|
120
Neurocrine Biosciences
NBIX
$13.7B
| – | – |
-314,240
| Closed | -$44.6M | – |
|
121
Ocular Therapeutix
OCUL
$1.62B
| – | – |
-157,300
| Closed | -$1.91M | – |
|
122
PMV Pharmaceuticals
PMVP
$71.1M
| – | – |
-4,975,291
| Closed | -$6.22M | – |
|
123
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-1,642,891
| Closed | -$55.6M | – |
|
|
RNAM
124
DELISTED
Avidity Biosciences
RNAM
| – | – |
-619,530
| Closed | -$44.7M | – |
|
125
Roivant Sciences
ROIV
$24.2B
| – | – |
-2,190,907
| Closed | -$47.5M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2026 Portfolio in Review
As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.
- OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
- OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
- OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
- OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
- OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
- OrbiMed opened 26 new positions and closed 22 in Q1 2026.
- OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.